Skip to main content

Drug Safety

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.



Rheumatic and autoimmune patients were not

Read Article
Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

Jan 12, 2022

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
JIA,knee,synovitis

What Can JIA Patients Expect 18 Years In?

MedPage Today
Jan 12, 2022

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.



More than two-thirds of patients were using no drug therapies at year 18, even though only about half were in remission and

Read Article
There were significantly fewer FDA advisory committee meetings in 2021 (n=10), down dramatically from 35 in 2012, 29 in 2018. Nonetheless the FDA did approve 50 new drugs (NDA) in 2021. https://t.co/rSzHkIMEfg

Dr. John Cush @RheumNow( View Tweet )

Jan 11, 2022
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit!https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c
Dr. John Cush @RheumNow( View Tweet )
Jan 07, 2022
COVID,teen,young,man,mask

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children

Jan 05, 2022

Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
psor.elb_.jpg

Spesolimab, an IL-36 Blocker, in Pustular Psoriasis

Jan 03, 2022

The NEJM has published the results of a phase 2 randomized trial showing that the use of an interleukin-36 receptor inhibitor, spesolimab, resulted in rapid improvement of generalized pustular psoriasis (at 1 week), but that adverse events and infections were of concern with 12 weeks of

Read Article
covid vaccine needle vaccination

Safety of COVID-19 Vaccines in Rheumatic Patients

Jan 03, 2022

Since the introduction of COVID-19 vaccines in January 2021, rheumatologists have fully advocated the protective benefits of their use - yet many have rarely noted flares and reactive side effects worrisome to patients.  Now a multinational study shows that the use of COVID vaccination in

Read Article
Best of 2021:Hydroxychloroquine related hyperpigmentation appears as blue/ black discoloration of skin or mucosa, occurs in 7-30%; Recent report says ~5%; Risk factors include steroids, bruising, anti-coagulants & trauma - theyr slow to resolve if you D/C https://t.co/IJDolwNyDx

Dr. John Cush @RheumNow( View Tweet )

Jan 03, 2022
Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitorshttps://t.co/pNBLklf6tY https://t.co/siJV8uhQOf
Dr. John Cush @RheumNow( View Tweet )
Jan 02, 2022
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen

Read Article
heart.jpg (keep)

Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Stiffness,hand,MCP,joint,pain

Best of 2021: 11 Drugs That Cause Arthritis

Dec 27, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as the aching are asking, they are really thinking these joint complaints must be due to something.

Read Article
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
FDA.approved.jpg

Best of 2021: FDA Approves Anifrolumab in SLE

Dec 24, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article
fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations

Read Article
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Dec 21, 2021

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
Vaccine2.jpg (keep)

CDC Panel Recommends mRNA COVID Vaccines Over J&J Vaccine

Dec 17, 2021

The U.S. Centers for Disease Control and Prevention (CDC) yesterday recommended Americans has recommended the two authorised mRNA COVID-19 vaccines over Johnson & Johnson's adenovirus COVID-19 vaccine, primarily due to the rare reports of thrombosis with thrombocytopenia syndrome (TTS).

Read Article
×